NSE - Delayed Quote INR

Aarti Drugs Limited (AARTIDRUGS.NS)

Compare
488.60 -6.40 (-1.29%)
At close: 3:30 PM GMT+5:30

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.
NameTitlePayExercisedYear Born
Mr. Prakash Moreshwar Patil Chairman, MD, CEO & Head of BR 27.85M -- 1947
Mr. Harshit Manila Savla Joint MD & Executive Director 25.54M -- 1962
Mr. Adhish Prakash Patil CFO & COO -- -- 1983
Mr. Rushikesh Vivek Deole Company Secretary & Compliance Officer -- -- --
Mr. Harit Pragji Shah Whole-Time Director 25.54M -- 1963
Mr. Uday Moreshwar Patil Whole-Time Director 3.35M -- 1963
Mr. Rashesh Chandrakant Gogri MD & Executive Director 25.54M -- 1974
Mr. Dhanaji L. Kakade Vice President of Technical -- -- --
Mr. Vishwa Harshit Savla Managing Director of the Pinnacle Life Science Private Limited -- -- --

Aarti Drugs Limited

Mahendra Industrial Estate
Ground Floor Road No. 29, Plot No. 109-D Sion (East)
Mumbai, 400 022
India
91 22 2401 9025 https://www.aartidrugs.co.in
Sector:?
Healthcare
Full Time Employees:?
1,064

Description

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for the antioxidant, antifungal, cardiovascular, and antidiabetic therapeutic areas. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Corporate Governance

Aarti Drugs Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

October 24, 2024 at 10:59 AM UTC

Aarti Drugs Limited Earnings Date

Recent Events

February 6, 2024 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers